Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Emerging Drugs and Targets for Alzheimer's Disease -

Emerging Drugs and Targets for Alzheimer's Disease

Volume 2: Neuronal Plasticity

Ana Martinez (Herausgeber)

Buch | Hardcover
326 Seiten
2010
Royal Society of Chemistry (Verlag)
978-1-84973-064-8 (ISBN)
CHF 249,95 inkl. MwSt
  • Lieferbar (Termin unbekannt)
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently in pharmaceutical development or new targets under the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs.
Alzheimer's disease is the most prevalent neurodegenerative disorder in the elderly. A recent study from the Bloomberg School of Public Health recently estimated that over 26 million people were living with the disease in 2006 and that the global prevalence of the disease will grow to 106 million by 2050. By that time, 43 per cent of those living with the disease will need high-level care, equivalent to that of a nursing home. However, even if modest advances in preventing or delaying the disease's progression were made, it could have a huge impact on global public health. According to this study, interventions that could delay the onset of the disease by as little as one year would reduce the prevalence of the disease by 12 million fewer cases in 2050. These figures reinforce how important it is to find an effective intervention for Alzheimer's disease.


Emerging Drugs and Targets for Alzheimer's Disease collects some of the most outstanding examples of new drugs currently under pharmaceutical development or new targets in the validation process that will reach the Alzheimer's drug market over the next few years as disease modifying drugs. Written by a team of distinguished experts, these volumes are an essential resource for scientists in the pharmaceutical and biotechnology industries and academics working in the neurosciences field.

Ana Martinez obtained her PhD in Organic Chemistry from the Complutense University of Madrid before becoming a researcher at the Medicinal Chemistry Institute of the Spanish National Council for Research (CSIC). Since 1995, her interests have focused on neurodegenerative disorders and she has led numerous research projects on the medicinal chemistry and rational drug design with the aim of finding new treatments for Alzheimer's disease. In February 2002, she joined NeuroPharma (now NOSCIRA) as R&D Director where she led projects from the discovery of potential new therapies to the final proof of concept in animal models. In February 2008, she returned to her academic position at the Medicinal Chemistry Institute (CSIC) leading several projects on neurodegenerative disease therapies and acting as an external scientific advisor to a number of pharmaceutical companies. Her main areas of research currently involve GSK-3 inhibitors and dual binding site acetylcholinesterase inhibitors. She has authored over a hundred and fifty scientific publications and has more than twenty active patents in the field.

Neuronal Plasticity as target;

Chapter 15: Regeneration of Degenerated Brain: A Promising Therapeutic Target;

Chapter 16: Promoting synaptic resilience in AD patients through PDE inhibition;

Chapter 17: A new generation of non invasive NGF-based therapies for Alzheimer's disease;

Chapter 18: Possible clinical applications of stem cell strategies in AD therapies;

Neuronal protection as target;

Chapter 19: Targeting Oxidative Mechanisms in Alzheimer Disease;

Chapter 20: Davunetide (NAP) Pharmacology: Neuroprotection and tau;

Chapter 21: Targeting NF- B inflammatory and pro-survival signaling in AD;

Chapter 22: PPAR in Alzheimer`s disease;

Miscellaneous targets and strategies;

Chapter 23: Serotonin 5-HT4 receptors as pharmacological targets for the treatment of Alzheimer¦s disease;

Chapter 24: Liver X Receptors as potential therapeutic target for AD;

Chapter 25: Discovery of memoquin, a multi-target-directed ligand for the treatment of Alzheimer's disease;

Chapter 26: RNA interference of genes related to AD;

Chapter 27: Medicinal plants, phytochemicals and Alzheimer's Disease

Reihe/Serie Drug Discovery ; Volume 3
Verlagsort Cambridge
Sprache englisch
Maße 156 x 234 mm
Gewicht 1398 g
Themenwelt Medizin / Pharmazie Medizinische Fachgebiete Geriatrie
Medizin / Pharmazie Medizinische Fachgebiete Neurologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
ISBN-10 1-84973-064-4 / 1849730644
ISBN-13 978-1-84973-064-8 / 9781849730648
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich

von Gisela Mötzing; Susanna Schwarz

Buch | Softcover (2022)
Urban & Fischer in Elsevier (Verlag)
CHF 46,15
Das Wichtigste für Ärztinnen und Ärzte aller Fachrichtungen

von Klaus Hager; Olaf Krause

Buch | Softcover (2021)
Urban & Fischer in Elsevier (Verlag)
CHF 51,80
Zukunftssicherheit der Geriatrie - Konzept und Bedarfszahlen

von Bundesverband Geriatrie e.V.

Buch | Softcover (2023)
Kohlhammer (Verlag)
CHF 49,95